Sanfilippo Roberta, Dileo Palma, Blay Jean-Yves, Constantinidou Anastasia, Le Cesne Axel, Benson Charlotte, Vizzini Laura, Contu Marianna, Baldi Giacomo G, Dei Tos Angelo P, Casali Paolo G
aAdult Mesenchymal Tumor Medical Oncology Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan bDepartment of Oncology, General Hospital of Agrigento, Agrigento cDepartment of Oncology, Ospedale Civile SS Annunziata Sassari, Sassari dMedical Oncology Unit, University Hospital S. Chiara, Pisa eDepartment of Anatomic Pathology, General Hospital of Treviso, Treviso, Italy fDepartment of Oncology, University College of London Hospital gSarcoma Unit, Royal Marsden, London, UK hCentre Leon Berard, Lyon iInstitut Gustave Roussy, Villejuif, France.
Anticancer Drugs. 2015 Jul;26(6):678-81. doi: 10.1097/CAD.0000000000000228.
Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%. The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.
转移性滑膜肉瘤患者的治疗选择有限。近年来，曲贝替定已成为对蒽环类药物和异环磷酰胺耐药的晚期软组织肉瘤患者的有效药物。本回顾性分析的目的是研究曲贝替定在滑膜肉瘤亚组中的疗效。对2000年至2013年间在四个欧洲参考肉瘤中心以及意大利罕见癌症网络接受曲贝替定治疗的晚期滑膜肉瘤患者进行了回顾性分析。回顾性评估了放射学反应、无进展生存期和总生存期，以及严重和意外不良事件。确定了61例转移性滑膜肉瘤患者。既往化疗方案的中位数为2（范围1 - 6）。9例患者部分缓解，另有2例轻微缓解，19例患者病情稳定，总缓解率为15%，肿瘤控制率为50%。无进展生存期的中位数为3个月，23%的患者在6个月时无进展。缓解患者的无进展生存期中位数为7个月。曲贝替定是转移性滑膜肉瘤部分患者姑息治疗的一种选择。
